Funded Projects › FP7
ETOX · Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities
The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modelling of the complex relationships existingbetween molecular and in vitro information and the in vivo toxicity outcomes of drugs. The proposed strategy includes a synergetic integration of innovative approaches in the following areas:Database building and management, including masking procedures for sensitive data, with the aim of facilitating the sharing of information among pharmaceutical companies.• Ontologies and text mining techniques, with the purpose of facilitating knowledge extraction from legacy preclinical reports and biomedical literature.• Chemistry and structure-based approaches for the molecular description of the compounds considered, as well as of the biological anti-targets responsible for the secondary pharmacologies.• Prediction of absorption and metabolism since these ADME properties are often critically related to toxicological events.• Computational genomics to afford the inter-species and inter-individual variabilities that complicate the interpretation of experimental and clinical outcomes.• Systems biology approaches in order to cope with the complex biological mechanisms which govern in vivo safety problems.• Sophisticated statistical analysis tools required to derive the inevitably highly-multivariate QSAR models.• Development and validation (according to the OECD principles) of QSARs, integrative models, expert systems and meta-tools.• Linkage of toxicity preclinical data with human outcomes
Consortium · 30 organisations
NOVARTIS PHARMA AG
CH
FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
ES · €400,025
CHEMOTARGETS SL
ES · €291,020
PFIZER LIMITED
UK
SANOFI-AVENTIS DEUTSCHLAND GMBH
DE
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
UK
STICHTING VU
NL · €356,528
EUROPEAN MOLECULAR BIOLOGY LABORATORY
DE · €608,090
UNIVERSITAT WIEN
AT · €357,140
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
DE · €96,600
INTE:LIGAND SOFTWARE-ENTWICKLUNGS-UND CONSULTING GMBH
AT · €256,736
UCB PHARMA SA
BE
ASTRAZENECA AB
SE
MOLECULAR NETWORKS GMBH COMPUTERCHEMIE
DE · €597,872
F. HOFFMANN-LA ROCHE AG
CH
LIVERPOOL JOHN MOORES UNIVERSITY
UK · €393,176
Lead Molecular Design S.L.
ES · €327,020
Bayer Pharma AG
DE
H. LUNDBECK AS
DK
BOEHRINGER INGELHEIM INTERNATIONALGMBH
DE
DANMARKS TEKNISKE UNIVERSITET
DK · €424,352
FUNDACIO INSTITUT HOSPITAL DEL MAR D INVESTIGACIONS MEDIQUES
ES · €1,129,407
UNIVERSITAT POLITECNICA DE VALENCIA
ES · €50,471
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
NL · €87,336
UNIVERSITY OF LEICESTER
UK · €99,299
ESTEVE PHARMACEUTICALS, SA
ES
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
FR
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL
ES · €707,974
LHASA LIMITED
UK · €726,972
JANSSEN PHARMACEUTICA NV
BE
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.